{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:53:12Z","timestamp":1792795992562,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2024-C-003"],"award-info":[{"award-number":["CSH-2024-C-003"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CS2-21176"],"award-info":[{"award-number":["CS2-21176"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaut.2025.103493","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:52:33Z","timestamp":1760799153000},"page":"103493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes"],"prefix":"10.1016","volume":"157","author":[{"given":"Fu-Shun","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-9020","authenticated-orcid":false,"given":"Shiow-Ing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-9627","authenticated-orcid":false,"given":"Chii-Min","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5753-9654","authenticated-orcid":false,"given":"Chien-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103493_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - Common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103493_bib2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103493_bib3","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"National burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaut.2025.103493_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","article-title":"Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014","volume":"79","author":"Myasoedova","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.jaut.2025.103493_bib5","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.jfma.2019.06.016","article-title":"Trends in prevalence and incidence of diabetes mellitus from 2005 to 2014 in Taiwan","volume":"118","author":"Sheen","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.jaut.2025.103493_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jbspin.2016.09.001","article-title":"Rheumatoid arthritis, insulin resistance, and diabetes","volume":"84","author":"Nicolau","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.jaut.2025.103493_bib7","series-title":"Rheumatic Disease in Geriatrics: Diagnosis and Management","first-page":"173","article-title":"Rheumatoid arthritis","author":"Slobodin","year":"2020"},{"key":"10.1016\/j.jaut.2025.103493_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/XCE.0000000000000244","article-title":"The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis","volume":"10","author":"Tian","year":"2021","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.jaut.2025.103493_bib9","article-title":"Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study","volume":"9","author":"Lu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2025.103493_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.dsx.2020.12.042","article-title":"Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of cohort studies","volume":"15","author":"Charoenngam","year":"2021","journal-title":"Diabetes Metabol. Syndr."},{"key":"10.1016\/j.jaut.2025.103493_bib11","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1136\/annrheumdis-2014-205216","article-title":"Dipeptidyl peptidase-4 inhibitors in type 2 diabetes May reduce the risk of autoimmune diseases: a population-based cohort study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103493_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.jaut.2025.103493_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrrheum.2010.159","article-title":"The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis","volume":"6","author":"Sellam","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103493_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jaut.2025.103493_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105732","article-title":"The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"75","author":"Du","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jaut.2025.103493_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70201","article-title":"Anti-inflammatory mechanisms of antidiabetic therapies: metabolic regulation and inflammatory pathways","volume":"28","author":"Yen","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaut.2025.103493_bib17","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaut.2025.103493_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110692","article-title":"Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus","volume":"200","author":"Yen","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.jaut.2025.103493_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101783","article-title":"Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study","volume":"56","author":"Chang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jaut.2025.103493_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.16578","article-title":"Sodium-glucose Cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus","volume":"7","author":"Yen","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jaut.2025.103493_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/03009742.2019.1695928","article-title":"Adherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study","volume":"49","author":"Naffaa","year":"2020","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103493_bib22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1507\/endocrj.EJ20-0647","article-title":"Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk","volume":"68","author":"Wang","year":"2021","journal-title":"Endocr. J."},{"key":"10.1016\/j.jaut.2025.103493_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13804","article-title":"Association between thiazolidinedione use and rheumatoid arthritis risk in patients with type II diabetes, a population-based, case-control study","volume":"75","author":"Hsieh","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jaut.2025.103493_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672519","article-title":"Insulin signaling in arthritis","volume":"12","author":"Tripolino","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103493_bib25","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103493_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103453","article-title":"Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: a real-world evidence study","volume":"155","author":"Lee","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2025.103493_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2025.103493_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103493_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70199","article-title":"Glucagon-like Peptide-1 receptor agonists: multifaceted roles in immune and inflammatory regulation, glycemic control, and synergistic therapeutic applications","volume":"28","author":"Hsu","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaut.2025.103493_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s42255-023-00943-3","article-title":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","volume":"6","author":"Dwibedi","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.jaut.2025.103493_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced Obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaut.2025.103493_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70137","article-title":"Exploration and identification of potential biomarkers and immune cell infiltration analysis in synovial tissue of rheumatoid arthritis","volume":"28","author":"Liu","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaut.2025.103493_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15020","article-title":"Whether full-length IL-38 acts as a promoter or inhibitor in activating rheumatoid arthritis fibroblast-like synoviocytes depends on IL-1\u03b2","volume":"27","author":"Ding","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaut.2025.103493_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15287","article-title":"Knockdown of NFIL3 modulates the AMPK pathway to suppress excessive cell proliferation, inflammation, and migration in rheumatoid arthritis","volume":"27","author":"Qiang","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaut.2025.103493_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat. Rev. Cardiol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:33:04Z","timestamp":1778700784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S0896841125001386"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103493","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103493"}}